Phaseline

Targets › KDM1A

KDM1A (Lysine-specific histone demethylase 1A): drug programs, companies and trials

4 programs from 4 companies in 19 trials: 8 Phase 2, 8 Phase 1, 3 Phase 3; Oncology; next expected readout Dec 2026.

Histone demethylase that can demethylate both 'Lys-4' (H3K4me) and 'Lys-9' (H3K9me) of histone H3, thereby acting as a coactivator or a corepressor, depending on the context. Acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. (UniProt, O60341)

Open in Phaseline: the race on KDM1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Merck & Co. (MSD)Bomedemstat (MK-3543)
Lysine-specific histone demethylase 1 inhibitor
KDM1APhase 3Essential Thrombocythemia; Thrombocythemia, Essential; Polycythemia Vera; Acute Myeloid LeukemiaJul 2027
Daiichi SankyoValemetostat Tosylate
EZH1/2 dual inhibitor
EZH1, EZH2, KDM1APhase 2Relapsed/Refractory Peripheral T-Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Lymphoma, B-Cell …Mar 2028
Oryzon GenomicsIadademstat
LSD1 inhibitor
KDM1APhase 1Acute Myeloid Leukemia, in Relapse; Accelerated Phase Myeloproliferative Neoplasm; Acute Myeloid Leukemia; Extensive Stage Lung Small Cell Carcinoma …Dec 2026
M.D. Anderson Cancer CenterSeclidemstat
LSD1 inhibitor
KDM1APhase 1Chronic Myelomonocytic Leukemia-0Sep 2027

Conditions

Essential Thrombocythemia (3) Thrombocythemia, Essential (2) Acute Myeloid Leukemia (2) Polycythemia Vera (1) Acute Myeloid Leukemia, in Relapse (1) Accelerated Phase Myeloproliferative Neoplasm (1) Extensive Stage Lung Small Cell Carcinoma (1) Extensive Stage Small Cell Lung Cancer (ES-SCLC) (1) Relapsed/Refractory Peripheral T-Cell Lymphoma (1) Non-small Cell Lung Cancer (1) Advanced Solid Tumor (1) Lymphoma, B-Cell (1)

Modalities

small molecule (3), mixed (1)

Companies

Merck & Co. (MSD) (1) Oryzon Genomics (1) Daiichi Sankyo (1) M.D. Anderson Cancer Center (1)

Related targets

EZH1 (1) EZH2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.